Kineta (KANT) 10-Q2018 Q1 Quarterly report

Filed: 9 May 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abundance, accredited, adequacy, assumption, ATM, banking, bifurcated, Bio, Boston, breakthrough, CFF, Chamber, clarified, CMC, compound, constrained, constraint, consummated, consummation, contemplated, context, creditworthy, damage, default, derecognized, displayed, disposition, distinct, dividend, Eloxx, embedded, escalating, evidence, expedient, explain, fit, fixed, Flatley, Floor, framework, frequent, hindered, hindsight, hoc, host, incremental, incrementally, indefinitely, input, iv, July, labor, land, largest, lessee, lessor, licensee, LLC, low, mg, mid, model, mutually, NOL, Nonrefundable, objective, overcome, path, pattern, payroll, plc, pre, progression, project, proportional, prudent, PTI, purpose, qualitatively, quantitatively, randomized, recipient, Reciprocal, reclassified, reconciling, recoverability, recoverable, recovery, reevaluate, rescind, residual, retirement, reversal, reverse, RSU, secondary, segment, shelf, simplified, singular, split, Spyryx, standalone, step, substance, Summary, Symdeko, synthesized, tangible, taxable, territory, typically, unallocated, underperformance, underwritten, undiscounted, universal, unmet, unrecognized, unsatisfied, unusual, Ussing, Verona, wholly

Removed: accretion, acted, Baird, closed, computing, converted, deducting, Deferral, dysfunction, fourth, Idec, participating, percent, principle, RBC, redeemable, underwriting, undistributed, unit, Wainwright

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

KANT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Proteostasis Therapeutics, Inc. (the “Company”) for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Meenu Chhabra, President and Chief Executive Officer (Principal Executive Officer) hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

1)	the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2018

/s/ Meenu Chhabra

Meenu Chhabra

President and Chief Executive Officer

(Principal Executive Officer)

In connection with the quarterly report on Form 10-Q of Proteostasis Therapeutics, Inc. (the “Company”) for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Helen M. Boudreau, Chief Financial Officer (Principal Financial Officer) hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

(1)	the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2018

/s/ Helen M. Boudreau

Helen M. Boudreau

Chief Financial Officer

(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.